Stacey Anne Gould1, Henri Doods1, Thorsten Lamla1, Anton Pekcec2. 1. Boehringer Ingelheim Pharma GmbH & Co. KG, Div. Research Germany, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany. 2. Boehringer Ingelheim Pharma GmbH & Co. KG, Div. Research Germany, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany. Electronic address: anton.pekcec@boehringer-ingelheim.com.
Abstract
BACKGROUND: It has recently been suggested that non-reflex behavioral readouts, such as burrowing, may be used to evaluate the efficacy of analgesics in rodent models of pain. OBJECTIVE: To confirm whether intraplantar Complete Freund's Adjuvant (CFA)-induced pain reliably results in burrowing deficits which can be ameliorated by clinically efficacious analgesics as previously suggested. METHODS: Uni- or bilateral intraplantar CFA injections were performed in male Wistar Han rats. The time- and concentration-response of burrowing deficits and the ability of various analgesics to reinstate burrowing performance were studied. An anxiolytic was also tested to evaluate the motivational cue that drives this behavior. RESULTS: Burrowing deficits were dependent on the concentration of CFA injected, most pronounced 24h after CFA injections and even more pronounced after bilateral compared with unilateral injections. Celecoxib and ibuprofen reversed CFA-induced burrowing deficits whereas indomethacin failed to significantly reinstate burrowing performance. Morphine and tramadol failed to reinstate burrowing performance, but sedation was observed in control rats at doses thought to be efficacious. An antibody directed against the nerve growth factor significantly improved CFA-induced burrowing deficits. Neither gabapentin nor the anxiolytic diazepam reinstated burrowing performance and the opportunity to find shelter did not modify burrowing performance. CONCLUSION: Burrowing is an innate behavior reliably exhibited by rats. It is suppressed in a model of inflammatory pain and differently reinstated by clinically efficacious analgesics that lack motor impairing side effects, but not an anxiolytic, suggesting that this assay is suitable for the assessment of analgesic efficacy of novel drugs.
BACKGROUND: It has recently been suggested that non-reflex behavioral readouts, such as burrowing, may be used to evaluate the efficacy of analgesics in rodent models of pain. OBJECTIVE: To confirm whether intraplantar Complete Freund's Adjuvant (CFA)-induced pain reliably results in burrowing deficits which can be ameliorated by clinically efficacious analgesics as previously suggested. METHODS: Uni- or bilateral intraplantar CFA injections were performed in male Wistar Han rats. The time- and concentration-response of burrowing deficits and the ability of various analgesics to reinstate burrowing performance were studied. An anxiolytic was also tested to evaluate the motivational cue that drives this behavior. RESULTS: Burrowing deficits were dependent on the concentration of CFA injected, most pronounced 24h after CFA injections and even more pronounced after bilateral compared with unilateral injections. Celecoxib and ibuprofen reversed CFA-induced burrowing deficits whereas indomethacin failed to significantly reinstate burrowing performance. Morphine and tramadol failed to reinstate burrowing performance, but sedation was observed in control rats at doses thought to be efficacious. An antibody directed against the nerve growth factor significantly improved CFA-induced burrowing deficits. Neither gabapentin nor the anxiolytic diazepam reinstated burrowing performance and the opportunity to find shelter did not modify burrowing performance. CONCLUSION: Burrowing is an innate behavior reliably exhibited by rats. It is suppressed in a model of inflammatory pain and differently reinstated by clinically efficacious analgesics that lack motor impairing side effects, but not an anxiolytic, suggesting that this assay is suitable for the assessment of analgesic efficacy of novel drugs.
Authors: Sonny Hermanus Johannes Sliepen; Marta Diaz-Delcastillo; Johanna Korioth; Rikke Brix Olsen; Camilla Kristine Appel; Thomas Christoph; Anne-Marie Heegaard; Kris Rutten Journal: In Vivo Date: 2019 Jul-Aug Impact factor: 2.155
Authors: Xue Ying Zhang; Ahmed Barakat; Marta Diaz-delCastillo; Jan Vollert; Emily S Sena; Anne-Marie Heegaard; Andrew S C Rice; Nadia Soliman Journal: Pain Date: 2022-03-29 Impact factor: 7.926
Authors: Arjun Muralidharan; Andy Kuo; Meera Jacob; Jacintha S Lourdesamy; Lara Melo Soares Pinho De Carvalho; Janet R Nicholson; Laura Corradini; Maree T Smith Journal: Front Behav Neurosci Date: 2016-05-10 Impact factor: 3.558
Authors: Rachel Wodarski; Ada Delaney; Camilla Ultenius; Rosie Morland; Nick Andrews; Catherine Baastrup; Luke A Bryden; Ombretta Caspani; Thomas Christoph; Natalie J Gardiner; Wenlong Huang; Jeffrey D Kennedy; Suguru Koyama; Dominic Li; Marcin Ligocki; Annika Lindsten; Ian Machin; Anton Pekcec; Angela Robens; Sanziana M Rotariu; Sabrina Vo; Marta Segerdahl; Carina Stenfors; Camilla I Svensson; Rolf-Detlef Treede; Katsuhiro Uto; Kazumi Yamamoto; Kris Rutten; Andrew S C Rice Journal: Pain Date: 2016-10 Impact factor: 6.961